Amicus Therapeutics (FOLD)
(Delayed Data from NSDQ)
$9.81 USD
-0.04 (-0.41%)
Updated Jul 3, 2024 01:00 PM ET
After-Market: $9.82 +0.01 (0.10%) 7:58 PM ET
4-Sell of 5 4
F Value A Growth C Momentum C VGM
Balance Sheet
Fiscal Year End for Amicus Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 286 | 294 | 483 | 483 | 453 |
Receivables | 88 | 66 | 53 | 47 | 33 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 60 | 24 | 27 | 20 | 14 |
Other Current Assets | 50 | 40 | 35 | 30 | 20 |
Total Current Assets | 483 | 424 | 597 | 579 | 520 |
Net Property & Equipment | 32 | 31 | 43 | 44 | 48 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 218 | 198 | 198 | 198 | 198 |
Deposits & Other Assets | 19 | 42 | 47 | 42 | 51 |
Total Assets | 778 | 724 | 905 | 887 | 850 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 15 | 15 | 22 | 17 | 120 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 144 | 94 | 98 | 97 | 0 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 21 | 19 | 9 | 1 |
Total Current Liabilities | 168 | 139 | 146 | 130 | 129 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 10 | 11 | 12 | 14 |
Convertible Debt | 0 | 0 | 0 | 0 | 2 |
Long-Term Debt | 388 | 392 | 389 | 389 | 147 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 13 | 9 | 8 | 23 | 28 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 618 | 601 | 598 | 600 | 374 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 3 | 3 | 3 | 3 | 3 |
Capital Surplus | 2,836 | 2,665 | 2,595 | 2,309 | 2,227 |
Retained Earnings | -2,684 | -2,532 | -2,296 | -2,045 | -1,769 |
Other Equity | 5 | -12 | 5 | 21 | 15 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 160 | 123 | 307 | 286 | 476 |
Total Liabilities & Shareholder's Equity | 778 | 724 | 905 | 887 | 850 |
Total Common Equity | 160 | 123 | 307 | 286 | 476 |
Shares Outstanding | 293.20 | 280.90 | 278.60 | 260.50 | 254.80 |
Book Value Per Share | 0.55 | 0.44 | 1.10 | 1.10 | 1.87 |
Fiscal Year End for Amicus Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 240 | 286 | 280 | 266 | 267 |
Receivables | 76 | 88 | 73 | 64 | 68 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 61 | 60 | 57 | 51 | 27 |
Other Current Assets | 54 | 50 | 53 | 52 | 37 |
Total Current Assets | 431 | 483 | 463 | 433 | 400 |
Net Property & Equipment | 32 | 32 | 31 | 30 | 31 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 217 | 218 | 219 | 220 | 198 |
Deposits & Other Assets | 18 | 19 | 21 | 19 | 43 |
Total Assets | 722 | 778 | 764 | 730 | 701 |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 9 | 15 | 23 | 14 | 25 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 125 | 144 | 139 | 125 | 93 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 13 | 13 |
Total Current Liabilities | 142 | 168 | 169 | 159 | 138 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 6 | 6 | 6 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 388 | 388 | 394 | 393 | 393 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 13 | 9 | 9 | 10 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 591 | 618 | 631 | 619 | 598 |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 3 | 3 | 3 | 3 | 3 |
Capital Surplus | 2,854 | 2,836 | 2,787 | 2,733 | 2,692 |
Retained Earnings | -2,732 | -2,684 | -2,650 | -2,629 | -2,585 |
Other Equity | 7 | 5 | -7 | 4 | -7 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 131 | 160 | 133 | 112 | 103 |
Total Liabilities & Shareholder's Equity | 722 | 778 | 764 | 730 | 701 |
Total Common Equity | 131 | 160 | 133 | 112 | 103 |
Shares Outstanding | 296.20 | 293.20 | 293.20 | 284.50 | 283.30 |
Book Value Per Share | 0.44 | 0.55 | 0.45 | 0.39 | 0.36 |